INK4a gene expression and methylation in primary breast cancer: Overexpression of p16(INK4a) messenger RNA is a marker of poor prognosis

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2777-2787

  Hui, Rina ^a   Macmillan, R Douglas ^b   Kenny, Frances S ^b   Musgrove, Elizabeth A ^a   Blamey, Roger W ^b   Nicholson, Robert I ^c   Robertson, John F R ^b   Sutherland, Robert L ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; PROTEIN P16;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CLINICAL FEATURE; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; METHYLATION; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CARRIER PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA, NEOPLASM; EXONS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; RNA, MESSENGER; SURVIVAL RATE; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0033926203     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
2. Hunter, T., and Pines, J. Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
3. 1 control. Cancer Res., 55: 4818-4823, 1995.
4. Koh, J., Enders, G. H., Dynlacht, B. D., and Harlow, E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature (Lond.), 375: 506-510, 1995.
5. Kamb, A., Gruis, N. A., Weaver, F. J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
6. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753-756, 1994.
7. Serrano, M., Lee, H., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R. A. Role of the INK4a locus in tumor suppression and cell mortality. Cell, 85: 27-37, 1996.
8. Barrett, M. T., Sanchez, C. A., Gaalipeau, P. C., Neshat, K., Emond, M., and Reid, B. J. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene, 13: 1867-1873, 1996.
9. Cairns, P., Shaw, M. F., and Knowles, M. A. Initiation of bladder cancer may involve deletion of a tumor suppressor gene on chromosome 9. Oncogene, 8: 1083-1085, 1993.
10. van der Riet, P. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res., 54: 1156-1158, 1994.
11. INk4a in oral premalignant lesions. Oncogene, 14: 1799-1803, 1997.
12. NK4a protein is restricted to the subset of lung cancer lines that retains wild type RB. Oncogene, 9: 3375-3378, 1994.
13. INK4/MTS1 tumour suppressor gene product. EMBO J., 14: 503-511, 1995.
14. INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res., 56: 5557-5562, 1996.
15. Khleif, S. N., DeGregori, J., Yee, C. L., Otterson, G. A., Kaye, F. J., Nevins, J. R., and Howley, P. M. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc. Natl. Acad. Sci. USA, 93: 4350-4354, 1996.
16. Dublin, E. A., Patel, N. K., Gillett, C. E., Smith, P., Peters, G., and Barnes, D. M. Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int. J. Cancer, 79: 71-75, 1998.
17. Li, Y., Nichols, M. A., Shay, J. W., and Xiong, Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res., 54: 6078-6082, 1994.
18. Fang, X. J., Jin, X. M., Xu, H. J., Liu, L., Peng, H. Q., Hogg, D., Roth, J. A., Yu, Y. H., Xu, F. J., Bast, R. C., and Mills, G. B. Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene, 16: 1-8, 1998.
19. Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., and Bartek, J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (Lond.), 375: 503-506, 1995.
20. INK4a transcript. Cancer Res., 55: 2995-2997, 1995.
21. Stone, S., Jiang, P., Dayananth, P., Tavtigian, S. V., Katcher, H., Parry, D., Peters, G., and Kamb, A. Complex structure and regulation of the p16 (MTS1) locus. Cancer Res., 55: 2988-2994, 1995.
22. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 83: 993-1000, 1995.
23. INK4a: a gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression. Oncogene, 12: 2041-2044, 1996.
24. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92: 713-723, 1998.
25. Zhang, Y., Xiong, Y., and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92: 725-734, 1998.
26. INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta, 1378: F115-F177, 1998.
27. Reed, A. L., Califano, J., Cairns, P., Westra, W. H., Jones, R. M., Koch, W., Ahrendt, S., Eby, Y., Sewell, D., Nawroz, H., Bartek, J., and Sidransky, D. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res., 56: 3630-3633, 1996.
28. Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., and Kern, S. E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet., 8: 27-32, 1994.
29. Schutte, M., Hruban, R. H., Geradts, J., Maynard, R., Hilgers, W., Rabindran, S. K., Moskaluk, C. A., Hahn, S. A., Schwartewaldhoff, I., Schmiegel, W., Baylin, S. B., Kern, S. E., and Herman, J. G. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res., 57: 3126-3130, 1997.
30. Berns, E. M., Klijn, J. G., Smid, M., van Staveren, I. L., Gruis, N. A., and Foekens, J. A. Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. Br. J. Cancer, 72: 964-967, 1995.
31. WAF1/CIP1 in human breast cancer. Int. J. Cancer, 63: 584-591, 1995.
32. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
33. INK4B. Cancer Res., 56: 722-727, 1996.
34. Fizzotti, M., Cimino, G., Pisegna, S., Alimena, G., Quartarone, C., Mandelli, F., Pelicci, P. G., and Coco, F. L. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukaemia and association with adverse prognostic features. Blood, 85: 2685-2690, 1995.
35. INK4 expression is frequent in high-grade gliomas. Cancer Res., 55: 1941-1945, 1995.
36. Reed, J. A., Loganzo, F. J., Shea, C. R., Walker, G. J., Flores, J. F., Glendening, J. M., Bogdany, J. K., Shiel, M. J., Haluska, F. G., Fountain, J. W., and Albino, A. P. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res., 55: 2713-2718, 1995.
37. INK4a expression in resected non-small cell lung tumors. Cancer Res., 56: 3415-3420, 1996.
38. ink4b gene deletions in childhood acute lymphoblastic leukaemia. Pediatr. Haematol. Oncol., 14: 141-150, 1997.
39. Kees, U. R., Burton, P. R., Lu, C., and Baker, D. L. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukaemia is associated with unfavorable clinical outcome. Blood, 89: 4161-4166, 1997.
40. INK4 expression in non-small cell lung carcinoma. Cancer (Phila.), 80: 389-395, 1997.
41. Hu, Y-X., Watanabe, H., Ohtsubo, K., Yamaguchi, Y., Ha, A., Okai, T., and Sawabu, N. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin. Cancer Res., 3: 1473-1477, 1997.
42. Straume, O., and Akslen, L. A. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int. J. Cancer, 74: 535-539, 1997.
43. Garcia-Sanz, R., Gonzalez, M., Vargas, M., Chillon, M. C., Balanzategui, A., Barbon, M., Flores, M. T., and San Miguel, J. F. Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphoma. Leukemia (Baltimore), 11: 1915-1920, 1997.
44. Takeuchi, H., Ozawa, S., Ando, N., Shih, C. H., Koyanagi, K., Ueda, M., and Kitajima, M. Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin. Cancer Res., 3: 2229-2236, 1997.
45. INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer. Int. J. Oncol., 12: 1111-1116, 1998.
46. Eiriksdottir, G., Sigurdsson, A., Jonasson, J. G., Agnarsson, B. A., Sigurdsson, H., Gudmundsson, J., Bergthorsson, J. T., Barkardottir, R. B., Egilsson, V., and Ingvarsson, S. Loss of heterozygosity on chromosome 9 in human breast cancer: association with clinical variables and genetic changes at other chromosome regions. Int. J. Cancer, 64: 378-382, 1995.
47. An, H. X., Niederacher, D., Picard, F., van Roeyen, C., Bender, H. G., and Beckmann, M. W. Frequent allele loss on 9p21-22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer. Genes Chromosomes Cancer, 17: 14-20, 1996.
48. Kenny, F. S., Hui, R., Musgrove, E. A., Gee, J. M., Blamey, R. W., Nicholson, R. I., Sutherland, R. L., and Robertson, J. F. R. Overexpression of cyclin D1 mRNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin. Cancer Res., 5: 2069-2075, 1999.
49. Hui, R., Cornish, A. L., McClelland, R. A., Robertson, J. F. R., Blarney, R. W., Musgrove, E. A., Nicholson, R. I., and Sutherland, R. L. Cyclin D1 and estrogen receptor mRNA expression are positively correlated in primary breast cancer. Clin. Cancer Res., 2: 923-928, 1996.
50. Hui, R., Ball, J. R., MacMillan, R. D., Prall, O. W. J., Campbell, D. H., Cornish, A. L., McClelland, R. A., Daly, R. J., Forbes, J. F., Blamey, R. W., Musgrove, E. A., Robertson, J. F. R., Nicholson, R. I., and Sutherland, R. L. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene, 16: 1053-1059, 1998.
51. Galea, M. H., Blamey, R. W., Elston, C. E., and Ellis, I. O. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res. Treat., 22: 207-219, 1992.
52. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
53. Lee, E. T. Statistical Methods for Survival Data Analysis. New York: John Wiley and Sons, 1992.
54. Guan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G., and Xiong, Y. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev., 8: 2939-2952, 1994.
55. ink4 requires functional retinoblastoma protein. Proc. Natl. Acad. Sci. USA, 92: 6289-6293, 1995.
56. Nielsen, N. H., Emdin, S. O., Cajander, J., and Landberg, G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene, 14: 295-304, 1997.
57. Buckley, M. F., Sweeney, K. J., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., deFazio, A., Watts, C. K., Musgrove, E. A., and Sutherland, R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8: 2127-2133, 1993.
58. 1-arrested human breast cancer cells. Oncogene, 12: 2315-2324, 1996.
59. Foster, J. S., and Wimalasena, J. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol. Endocrinol., 10: 488-498, 1996.
60. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-cdk2. J. Biol. Chem., 272: 10882-10894, 1997.
61. Michalides, R., Hageman, P., Vantinteren, H., Houben, L., Wientjens, E., Klompmaker, R., and Peterse, J. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br. J. Cancer, 73: 728-734, 1996.
62. Gottardis, M. M., Saceda, M., Garcia-Morales, P., Fung, Y-K., Solomon, H., Sholler, P. F., Lippman, M. E., and Martin, M. B. Regulation of retinoblastoma gene expression in hormone-dependent breast cancer. Endocrinology, 136: 5659-5665, 1995.
63. Berns, E. M., de Klein, A., van Putten, W. L., van Staveren, I. L., Bootsma, A., Klijn, J. G., and Foekens, J. A. Association between RB-1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival. Int. J. Cancer, 64: 140-145, 1995.
64. Jones, P. A. DNA methylation errors and cancer. Cancer Res., 56: 2463-2467, 1996.
65. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
66. Ink4. Cancer Res., 54: 5816-5820, 1994.
67. Pietilainen, T., Lipponen, P., Aaltomaa, S., Eskelinen, M., Kosma, V. M., and Syrjanen, K. Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survival. Eur. J. Cancer, 3: 329-333, 1995.
68. INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int. J. Cancer, 74: 57-63, 1997.